HLA Protein Technologies Secures NCI TCR License

HLA Protein Technologies, Inc., a private company based in Oklahoma City, announced on August 11, 2026, that it has secured an internal use license from the United States — National Cancer Institute (NCI), a component of the United States — National Institutes of Health (NIH). The license covers advanced T-cell receptor (TCR) compositions and methods, granting HLA Protein Technologies access to cell lines engineered to express clinically relevant T-cell receptors. This license enables the company to expand its HLA and TCR portfolio and manufacturing activities, and to develop new HLA-based research tools, including tetramer reagents, that aim to reduce development timelines in immunotherapy and oncology. The company plans to integrate these tools with its existing HLA Peptide Binding Services to deliver faster screening of candidate epitopes and accelerate the development of next-generation immunotherapies. The announcement was supported by Michelle Gregory, Director of Life Science Oklahoma, and Dr. Rico Buchli, Chief Scientific Officer at HLA Protein Technologies.